Urovant gets rights to gene therapy for overactive bladder

Ion Channel Innovations LLC (Ardsley, N.Y.) granted Urovant Sciences Ltd. (Basel, Switzerland) rights to develop and commercialize hMaxi-K, a gene therapy in development for overactive bladder. Next year, Urovant plans to start a Phase II trial of the therapy to treat overactive bladder in patients who have failed oral pharmacologic therapy...